Granted Patent
B2
US 12,209,123 · App. 17/814,075 · Granted Jan 28, 2025
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
Inventors:
Anna Hansen (Dublin, IE); Xiaodong Xiao (Dublin, IE); Peter Pavlik (Dublin, IE); Yan Chen (Dublin, IE); Catherine Rachel Ettinger (Dublin, IE)
Assignee:
Horizon Therapeutics Ireland DAC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases.
Claims (25)
1. A method of treating an autoimmune disease, comprising administering to a subject in need thereof a pharmaceutically effective amount of a human monoclonal antibody that comprises:
(1) a heavy chain comprising: (i) a variable region (VH) that comprises the amino acid sequence of SEQ ID NO:1, and (ii) a human IgG1 heavy chain constant domain; and
(2) a light chain comprising: (i) a variable region (VL) that comprises the amino acid sequence of SEQ ID NO:2, and (ii) a human lambda light chain constant domain.
2. The method of claim 1 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO:61, and said light chain comprises the amino acid sequence of SEQ ID NO: 62.
3. The method of claim 1 , wherein said autoimmune disease is associated with increased level of FLT3L-expressing CD4+ T cells.
4. The method of claim 1 , wherein said autoimmune disease is systemic lupus erythematosus (SLE).
5. The method of claim 1 , wherein said autoimmune disease is Sjögren's syndrome.
6. The method of claim 1 , wherein said autoimmune disease is rheumatoid arthritis.
7. The method of claim 1 , wherein said autoimmune disease is nephritis.
8. The method of claim 1 , wherein said autoimmune disease is multiple sclerosis.
9. The method of claim 1 , wherein said autoimmune disease is psoriasis.
10. The method of claim 1 , further comprising administering to said subject a second immunoregulatory agent.
11. A human monoclonal antibody comprising:
(1) a heavy chain comprising: (i) a variable region (VH) that comprises the amino acid sequence of SEQ ID NO:1, and (ii) a human IgG1 heavy chain constant domain; and
(2) a light chain comprising: (i) a variable region (VL) that comprises the amino acid sequence of SEQ ID NO:2, and (ii) a human lambda light chain constant domain.
12. The antibody of claim 11 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO:61, and said light chain comprises the amino acid sequence of SEQ ID NO: 62.
13. A pharmaceutical formulation comprising the antibody of claim 11 , further comprising a pharmaceutically acceptable excipient.
14. The pharmaceutical formulation of claim 13 , wherein said excipient comprises a surfactant, a stabilizer, an isotonic agent, a buffer, or any combination thereof.
15. A nucleic acid encoding a human monoclonal antibody, said antibody comprises:
(1) a heavy chain comprising: (i) a variable region (VH) that comprises the amino acid sequence of SEQ ID NO:1, and (ii) a human IgG1 heavy chain constant domain; and
(2) a light chain comprising: (i) a variable region (VL) that comprises the amino acid sequence of SEQ ID NO:2, and (ii) a human lambda light chain constant domain.
16. The nucleic acid of claim 15 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO:61, and said light chain comprises the amino acid sequence of SEQ ID NO: 62.
17. A host cell comprising the nucleic acid of claim 15 .
18. The host cell of claim 17 , wherein said host cell is a Chinese hamster ovary (CHO) cell or a HEK293 cell.
19. A method of making the antibody of claim 11 , comprising (a) culturing a host cell expressing said antibody; and (b) isolating said antibody from said cultured host cell.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 22, 2024
From: VIELA BIO, INC.
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 067489/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 19, 2022
From: HANSEN, ANNA; XIAO, XIAODONG; PAVLIK, PETER; CHEN, YAN
To: VIELA BIO, INC.
Reel/Frame 061468/0294 →
CONFIRMATORY ASSIGNMENT
Recorded Oct 19, 2022
From: ETTINGER, CATHERINE RACHEL
To: VIELA BIO, INC.
Reel/Frame 061710/0244 →
Continuity (3)
Continuation
16969774
Provisional Application
62630571
· Feb 14, 2018
References Cited (164)
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4301144A
· Iwashita et al.
· 1981
[cited by applicant]
US 4495285A
· Shimizu et al.
· 1985
[cited by applicant]
US 4496689A
· Mitra
· 1985
[cited by applicant]
US 4609546A
· Hiratani
· 1986
[cited by applicant]
US 4640835A
· Shimizu et al.
· 1987
[cited by applicant]
US 4670417A
· Iwasaki et al.
· 1987
[cited by applicant]
US 4766106A
· Katre et al.
· 1988
[cited by applicant]
US 4791192A
· Nakagawa et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5554512A
· Lyman et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonberg et al.
· 1997
[cited by applicant]
US 5639641A
· Pedersen et al.
· 1997
[cited by applicant]
US 5641870A
· Rinderknecht et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5714352A
· Jakobovits
· 1998
[cited by applicant]
US 5723323A
· Kauffman et al.
· 1998
[cited by applicant]
US 5750373A
· Garrard et al.
· 1998
[cited by applicant]
US 5763192A
· Kauffman et al.
· 1998
[cited by applicant]
US 5766886A
· Studnicka et al.
· 1998
[cited by applicant]
US 5814476A
· Kauffman et al.
· 1998
[cited by applicant]
US 5817483A
· Kauffman et al.
· 1998
[cited by applicant]
US 5824514A
· Kauffman et al.
· 1998
[cited by applicant]
US 5885793A
· Griffiths et al.
· 1999
[cited by applicant]
US 5955358A
· Huse
· 1999
[cited by applicant]
US 5969108A
· Mccafferty et al.
· 1999
[cited by applicant]
US 5976862A
· Kauffman et al.
· 1999
[cited by applicant]
US 6172197B1
· McCafferty et al.
· 2001
[cited by applicant]
US 6180370B1
· Queen et al.
· 2001
[cited by applicant]
US 6204023B1
· Robinson et al.
· 2001
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6331431B1
· Glaser et al.
· 2001
[cited by applicant]
US 6521404B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6544731B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6555313B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6582915B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6593081B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6602994B1
· Cash et al.
· 2003
[cited by applicant]
US 6653068B2
· Frisch et al.
· 2003
[cited by applicant]
US 6706484B1
· Knappik et al.
· 2004
[cited by applicant]
US 7083784B2
· Dall'Acqua et al.
· 2006
[cited by applicant]
US 7264963B1
· Knappik et al.
· 2007
[cited by applicant]
US 7342110B2
· Hoffee et al.
· 2008
[cited by applicant]
US 7537932B1
· Hannum et al.
· 2009
[cited by applicant]
US 7538195B2
· Singh et al.
· 2009
[cited by applicant]
US 7557189B2
· Hoffee et al.
· 2009
[cited by applicant]
US 7635666B1
· McCafferty et al.
· 2009
[cited by applicant]
US 7723270B1
· McCafferty et al.
· 2010
[cited by applicant]
US 8647470B2
· Esser
· 2014
[cited by applicant]
US 20020160004A1
· Lyman et al.
· 2002
[cited by applicant]
US 20020160974A1
· Banchereau et al.
· 2002
[cited by applicant]
US 20050158313A1
· Rosen
· 2005
[cited by applicant]
US 20050261229A1
· Gillies et al.
· 2005
[cited by applicant]
US 20060142430A1
· Harrington et al.
· 2006
[cited by applicant]
US 20090263474A1
· Banchereau
· 2009
[cited by examiner]
US 20130156764A1
· Levis
· 2013
[cited by examiner]
US 20140308201A1
· Batt et al.
· 2014
[cited by applicant]
US 20210002360A1
· Hansen et al.
· 2021
[cited by applicant]
EP 0229246A2
· 1987
[cited by applicant]
WO WO8705330A1
· 1987
[cited by applicant]
WO WO9014424A1
· 1990
[cited by applicant]
WO WO9014430A1
· 1990
[cited by applicant]
WO WO9014443A1
· 1990
[cited by applicant]
WO WO9203461A1
· 1992
[cited by applicant]
WO WO9306213A1
· 1993
[cited by applicant]
WO WO9418219A1
· 1994
[cited by applicant]
WO WO9906834A2
· 1999
[cited by applicant]
WO WO02067760A2
· 2002
[cited by applicant]
WO WO2006020145A2
· 2006
[cited by applicant]
WO WO2009100309A2
· 2009
[cited by applicant]
WO WO2011113041A2
· 2011
[cited by applicant]
WO 2016024255
· 2016
[cited by applicant]
WO WO2019160976A1
· 2019
[cited by applicant]
Raglan et al., Int J Cancer. Oct. 1, 2019;145(7):1719-1730. doi: 10.1002/ijc.31961. Epub Feb. 20, 2019. PMID: 30387875.
[cited by examiner]
Gimbrone et al., Circ Res. Feb. 19, 2016;118(4):620-36. doi: 10.1161/CIRCRESAHA.115.306301. PMID: 26892962 PMCID: PMC4762052.
[cited by examiner]
Breijyeh et al., Molecules. Dec. 8, 2020;25(24):5789. doi: 10.3390/molecules25245789. PMID: 33302541 PMCID: PMC7764106.
[cited by examiner]
Kipriyanov et al., Mol Biotechnol. Jan. 2004;26(1):39-60. doi: 10.1385/MB:26:1:39. PMID: 14734823.
[cited by examiner]
Van Belle et al., J Autoimmun. Jun. 2010;34(4):445-52. doi: 10.1016/j.jaut.2009.11.010. Epub Dec. 9, 2009. PMID: 12490959 PMCID: PMC2803035.
[cited by examiner]
Al-Lazikani B., et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” Journal of molecular biology, Nov. 1997, vol. 273 (4), pp. 927-948.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research (1997) 25(17):3389-3402.
[cited by applicant]
Altschul S.F., et al. “Local Alignment Statistics,” Methods in Enzymology, 1996, vol. 266, pp. 460-480.
[cited by applicant]
Andersson S.E.M., et al., “Activation of Fms-Like Tyrosine Kinase 3 Signaling Enhances Survivin Expression in a Mouse Model of Rheumatoid Arthritis,” PLoS One, Oct. 17, 2012, vol. 7, No. 10, e47668, pp. 01-09.
[cited by applicant]
Aplin J.D., et al., “Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids,” Critical Reviews Biochemistry, May 1981, vol. 10, No. 4, pp. 259-306.
[cited by applicant]
Astier A.L., et al., “RNA Interference Screen in Primary Human T Cells Reveals FLT3 as a Modulator of IL-10 Levels,” Journal of Immunology, 2010, vol. 184, No. 2, pp. 685-693.
[cited by applicant]
Barbas C.F., et al., “In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-reactivity,” Proceedings of the National Academy of Sciences,…
[cited by applicant]
Boerner P., et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-primed Human Splenocytes,” Journal of Immunology, Jul. 1991, vol. 147, No. 1, pp. 86-95.
[cited by applicant]
Brennan M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science, Jul. 5, 1985, vol. 229, No. 4708, pp. 81-83.
[cited by applicant]
Carter P., et al., “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proceedings of the National Academy of Sciences, May 1992, vol. 89 (10), pp. 4285-4289.
[cited by applicant]
Chothia C., et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology, Aug. 20, 1987, vol. 196, No. 4, pp. 901-917.
[cited by applicant]
Clackson T., et al., “Making Antibody Fragments Using Phage Display Libraries,” Nature, Aug. 15, 1999, vol. 352, No. 6336, pp. 624-628.
[cited by applicant]
Cole S.P.C., et al., “The EBV-Hybridoma Technique and its Application to Human Lung Cancer,” Monoclonal Antibodies and Cancer Therapy, 1985, pp. 77-96.
[cited by applicant]
Dall'Acqua W.F., et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn),” Journal of Biological Chemistry, Aug. 18, 2006, vol. 281, No. 33, pp. 23514-23524.
[cited by applicant]
Deboy C.A., et al., “FLT-3 Expression and Function on Microglia in Multiple Sclerosis,” Experimental and Molecular Pathology, Oct. 1, 2010, vol. 89, No. 2, pp. 109-116 (18 pages).
[cited by applicant]
Edelman G.M., et al., “The Covalent Structure of an Entire GammaG Immunoglobulin Molecule,” Biochemistry, Mar. 21, 1969, vol. 63, pp. 78-85.
[cited by applicant]
Edge A.S.B., et al., “Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid,” Analytical Biochemistry, Nov. 15, 1981, vol. 118, No. 1, pp. 131-137.
[cited by applicant]
Examination Report for Singapore Application No. 11202007702U, mailed Mar. 11, 2022, 5 pages.
[cited by applicant]
Extended European Search Report for Application No. 19754925.6, mailed Oct. 19, 2021, 9 pages.
[cited by applicant]
Fiore N., et al., “Immature Myeloid and Plasmacytoid Dendritic Cells Infiltrate Renal Tubulointerstitium in Patients with Lupus Nephritis,” Molecular Immunology, Jan. 2008, vol. 45, No. 1, pp. 259-265.
[cited by applicant]
Gram H., et al., “In Vitro Selection And Affinity Maturation Of Antibodies From A Naive Combinatorial Immunoglobulin Library,” Proceedings of the National Academy of Sciences, Apr. 1992, vol. 89 (8), pp. 3576-3580.
[cited by applicant]
Guimond M., et al., “In Vivo Role of Flt3 Ligand and Dendritic Cells in NK Cell Homeostasis,” The Journal of Immunology, Mar. 15, 2010, vol. 184, No. 6, pp. 2769-2775.
[cited by applicant]
Hansen A.M., et al., “Elucidation of FLT3 Ligand-dependent Dendritic Cell Activity In Autoimmune Disease,” Presented at the 15th International Symposium on Dendritic Cells in Aachen, Germany, Jun. 10-14, 2018, 01 page.
[cited by applicant]
Holdgate N., et al., “Recent Advances in Primary Sjogren's Syndrome [version 1; referees: 3 approved],” F1000Research, 2016, 5(F1000 Faculty Revision)-1412, 10 Pages.
[cited by applicant]
Hoogenboom H.R., et al., “By-Passing Immunisation: Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, Sep. 20, 1992, vol. 227, No. 2, pp. 381-388.
[cited by applicant]
Horizon Therapeutics Pic, Virtual R&D Day Presentation, Sep. 29, 2021, 118 pages.
[cited by applicant]
Horizon Therapeutics Pic, Virtual R&D Day Remarks, Sep. 29, 2021, 24 pages.
[cited by applicant]
Huse W.D., et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Research Article, Dec. 8, 1989, vol. 246, pp. 1275-1281.
[cited by applicant]
International Search Report for International Application No. PCT/US2019/017877, mailed Jun. 25, 2019, 05 Pages.
[cited by applicant]
International Written Opinion for Application No. PCT/US2019/017877, mailed Jun. 25, 2019, 05 Pages.
[cited by applicant]
Jones P.T., et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature, May 1986, vol. 321, pp. 522-525.
[cited by applicant]
Karlin and Atschul, “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes,” Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990).
[cited by applicant]
Karlin S., et al., “Applications And Statistics For Multiple High-scoring Segments In Molecular Sequences,” Proceedings of National Academy of Sciences, Jun. 15, 1993, vol. 90, No. 12, pp. 5873-5877.
[cited by applicant]
Kohler, G., et al., “Pillars Article: Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature, Mar. 1975, vol. 256, No. 5517, pp. 495-497. The Journal of Immunology, Mar. 2005, 1:174(5):…
[cited by applicant]
Lemmon, M.A., et al., “Cell Signaling by Receptor Tyrosine Kinases”, Cell, 2010, 141, 1117-1134.
[cited by applicant]
Li X., et al., “Sniping the Scout: Targeting the Key Molecules in Dendritic Cell Functions for Treatment of Autoimmune Diseases,” Pharmacological Research, May 2016, vol. 107, pp. 27-41, ISSN: 1043-6618, XP029533460, DO…
[cited by applicant]
Lund J., et al., “Human Fc Gamma RI and Fc Gamma RII Interact with Distinct but Overlapping Sites on Human IgG,” Journal of Immunology, Oct. 15, 1991, vol. 147, No. 8, pp. 2657-2662.
[cited by applicant]
Mahmoud T.I., et al., “Autoimmune Manifestations in Aged Mice Arise from Early-Life Immune Dysregulation,” Science Translational Medicine, Oct. 19, 2016, vol. 8, No. 361: 361ra137, 27 Pages.
[cited by applicant]
Marks J.D., et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Nature Biotechnology, Jul. 1992, vol. 10 (7), pp. 779-783.
[cited by applicant]
Marks J.D., et al., “By-Passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage,” Journal of Molecular Biology, Dec. 1991, vol. 222, pp. 581-597.
[cited by applicant]
McCafferty J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature, Dec. 1990, vol. 348 (6301), pp. 552-554.
[cited by applicant]
Morgan A., et al., “The N-terminal End of the CH2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for Clq, FcγRI and FcγRIII Binding,” Immunology, Oct. 1995, vol. 86, No. 2, pp. 319-324.
[cited by applicant]
Morimoto K., et al., “Single-step Purification of F(ab′)2 Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW,” Journal…
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/969,774, mailed Jul. 11, 2022, 5 pages.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/969,774, mailed Jun. 16, 2022, 8 pages.
[cited by applicant]
Oganesyan V., et al., “Structural Characterization of a Human Fc Fragment Engineered for Lack of Effector Functions,” Acta Crystallographica Section D Biology Crystallography, May 14, 2008, vol. D64, pp. 700-704.
[cited by applicant]
Palucka A.K., et al., “The Interplay of Dendritic Cell Subsets in Systemic Lupus Erythematosus”, Immunology and Cell Biology, Oct. 2002, vol. 80, No. 5, pp. 484-488.
[cited by applicant]
Presta L.G., et al., “Humanization of an Antibody Directed Against IgE,” Journal of Immunology, Sep. 1, 1993, vol. 151, No. 5, pp. 2623-2632.
[cited by applicant]
Ramos M.I., et al., “FMS-Related Tyrosine Kinase 3 Ligand (FIt3L)/CD135 Axis in Rheumatoid Arthritis,” Arthritis Research and Therapy, 2013, vol. 15, No. R209, 13 pages.
[cited by applicant]
Ramos M.I.P., et al., “Absence of Fms-like Tyrosine Kinase 3 Ligand (Flt3L) Signalling Protects Against Collagen-induced Arthritis,” Annals of the Rheumatic Diseases, Jan. 2015, vol. 74 (1), pp. 211-219, XP055849443, GB…
[cited by applicant]
Riechmann L., et al., “Reshaping Human Antibodies for Therapy,” Nature, Mar. 1988, vol. 332, No. 24, pp. 323-327.
[cited by applicant]
Robinson D.R., et al., “The Protein Tyrosine Kinase Family of The Human Genome,” Oncogene, 2000, vol. 19, No. 49, pp. 5548-5557.
[cited by applicant]
Rothe C., et al., “The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity…
[cited by applicant]
Schier R., et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site,” Journal of Molecular Biolo…
[cited by applicant]
Search and Examination Report for Singapore Application No. 11202007702U, mailed Mar. 9, 2022, 2 pages.
[cited by applicant]
Sheets M.D., et al., “Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens,” Proceedings of the National Academy of Scienc…
[cited by applicant]
Sims M.J., et al., “A Humanized CD18 Antibody Can Block Function Without Cell Destruction,” Journal of Immunology, Aug. 15, 1993, vol. 151, No. 4, pp. 2296-2308.
[cited by applicant]
Sojar H.T., et al., “A Chemical Method for the Deglycosylation of Proteins,” Archives of Biochemistry and Biophysics, Nov. 15, 1987, vol. 259, No. 1, pp. 52-57.
[cited by applicant]
Stemmer W.P.C., “Rapid Evolution of a Protein in Vitro by DNA Shuffling,” Nature, Aug. 4, 1994, vol. 370, No. 6488, pp. 389-391.
[cited by applicant]
Thotakura N.R., et al., “Enzymatic Deglycosylation of Glycoproteins,” Methods in Enzymology, 1987, vol. 138, pp. 350-359.
[cited by applicant]
Tobon G.J., et al., “The Fms-Like Tyrosine Kinase 3 Ligand, a Mediator of B Cell Survival, is also a Marker of Lymphoma in Primary Sjogren's Syndrome,” Arthritis and Rheumatism, Nov. 2010, vol. 62, No. 11, pp. 3447-3456.
[cited by applicant]
“UniProtKB—P36888 (FLT3_Human),” UniProt Accession No. P36888, Jun. 1, 1994, 16 pages.
[cited by applicant]
“UniProtKB—Q00342 (FLT3_Mouse),” UniProt Accession No. Q00342, Apr. 1, 1993, 14 pages.
[cited by applicant]
“UniProtKB, Numero Accesion . A0A1F9WZN4_9BACT,” Uncharacterized Protein, Feb. 15, 2017, 05 pages.
[cited by applicant]
“UniProtKB, Numero Accesion. A0A1H6YLR2_9ACTN,” Haloacetate dehalogenase, Nov. 22, 2017, 04 pages.
[cited by applicant]
“UniProtKB, Numero Accesion. A0A1Q9DGW5_SYMMI,” Multidrug Resistance Protein 1, Apr. 12, 2017, 09 pages.
[cited by applicant]
Vaughan T.J., et al., “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library,” Nature Biotechnology, 1996, vol. 14, pp. 309-314.
[cited by applicant]
Verhoeyen M., et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, Mar. 25, 1988, vol. 239, No. 4847, pp. 1534-1536.
[cited by applicant]
Whartenby K.A., et al., “Inhibition of FL T3 signaling targets DCs to Ameliorate Autoimmune Disease,” PNAS, Nov. 15, 2005, vol. 102, No. 46, pp. 16741-16746.
[cited by applicant]
Xiao et al., “A High-Throughput Platform for Population Reformatting and Mammalian Expression of Phage Display Libraries To Enable Functional Screening as Full-Length IgG”, mAbs, (2017) 9:6, :996-1006.
[cited by applicant]
Xiao et al., “A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format”, PLoS ONE (2015)10(10): e0140691, 16 pages.
[cited by applicant]
Kazi et al., “FMS-Like tyrosine kinase 3/FLT3: From basic science to clinical implications,” Physiological Reviews, Published: May 8, 2019, 99(3), pp. 1433-1466.
[cited by applicant]
Wilson et al., “Dendritic cell Flt3—regulation, roles and repercussions for immunotherapy,” Immunology & Cell Biology, Oct. 2021, (9), pp. 962-971.
[cited by applicant]
Search Report issued to application No. CN201980013516.0, dated Mar. 28, 2024.
[cited by applicant]